|Mr. Marc Voigt||Chief Exec. Officer and Exec. Director||438.14k||N/A||44|
|Ms. Deanne Miller LLB||Chief Operating Officer, Gen. Counsel and Company Sec.||252.75k||N/A||40|
|Dr. Frédéric Triebel M.D., Ph.D.||Chief Scientific Officer & Chief Medical Officer||229.39k||N/A||62|
|Mr. Thomas Robert John Bloomfield BA (Hons), A.C.I.S., M.A.I.C.D.||Joint Company Sec.||N/A||N/A||N/A|
|Ms. Larisa Chisholm||Director of Industry Liaison & Devel. and Director of Intellectual Property||N/A||N/A||N/A|
Prima BioMed Ltd. engages in the research, development, and commercialization of medical biotechnology products in Australia. The company develops immunotherapeutic products for the treatment of various types of cancer. Its core technologies are based on the LAG-3 immune control mechanism, which plays a vital role in the regulation of the T cell immune response. The companys lead product candidate is IMP321, a recombinant protein, which is in Phase IIb clinical trials in metastatic breast cancer when used as a chemo-immunotherapy, as well as in Phase I clinical trials in metastatic melanoma. Its other products include IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company is also developing CVac, an autologous dendritic cell-based product through Phase II clinical trials for ovarian cancer patients in remission. Prima BioMed Ltd. has strategic partnership agreement with Wuxi Biologics Co. Ltd. for developing IMP321 and other LAG-3 related products. Prima BioMed Ltd. is based in Sydney, Australia.
Prima Biomed Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.